Evolus to Report First Quarter 2020 Financial Results and Provide a Business Update on Monday, May 11, 2020

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS) will release its first quarter 2020 financial results on May 11, 2020, after U.S. market close. The company, known for its innovative aesthetic product Jeuveau®, invites investors to join a conference call at 4:30 p.m. ET on the same day. Participants can access the call via specific dial-in numbers or through a live audio webcast on Evolus' Investor Relations page. A replay will be available for a limited time post-call. Evolus aims to revolutionize the beauty industry with its customer-centric approach and advanced technology.

NEWPORT BEACH, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its first quarter 2020 financial results and provide a business update on Monday, May 11, 2020 after the close of the U.S. financial markets.

Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question and answer session will follow management remarks.

The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers. The conference ID is 1819528.

A replay of the call will be available following its completion through May 18, 2020. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 1819528.

A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30 days following the completion of the call.

About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure^™ technology. Jeuveau^® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: http://www.evolus.com.

Jeuveau^® is a registered trademark of Evolus, Inc.
Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor Contact:
Ashwin Agarwal
Vice President, Finance, Investor Relations & Treasury
Tel: +1-949-284-4559
Email: IR@Evolus.com

Media Contact:
Crystal Muilenburg
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506
Email: media@evolus.com

FAQ

What are the financial results for Evolus, Inc. expected to be released on May 11, 2020?

Evolus will report its first quarter 2020 financial results on May 11, 2020.

How can I access the Evolus, Inc. conference call on May 11, 2020?

You can access the Evolus conference call by dialing (866) 916-2317 for domestic calls or (703) 925-2662 for international calls.

When is the Evolus, Inc. conference call scheduled?

The conference call is scheduled for May 11, 2020, at 4:30 p.m. ET.

Where can I find the webcast for Evolus, Inc.'s investor call?

The live audio webcast will be available on Evolus' Investor Relations page at their website.

What is Jeuveau® and how is it relevant to Evolus, Inc.?

Jeuveau® is a neurotoxin dedicated exclusively to aesthetics and is a key product from Evolus.